Management of pediatric pulmonary aspergillosis

Written By: user

IJCP Editorial Team

Published On: 07 Apr, 2023 3:43 PM | Updated On: 17 May, 2024 5:52 PM

Management of pediatric pulmonary aspergillosis

Invasive pulmonary aspergillosis (IPA) illustrates a severe illness in immunocompromised children; however, its optimal management still remains arguable. To better clarify this issue, the present study performed a literature search through reputed databases to identify current risk factors and diagnostic, therapeutic, and prophylactic methods for invasive pulmonary aspergillosis (IPA) in the pediatric population. It searched for observational studies and clinical trials regarding diagnosis, treatment, and prophylaxis and summarised the results. The study included five clinical trials and 25 observational studies (4453 patients).

The study observed-

Hematological malignancies, previous organ transplants, and other primary or acquired immunodeficiencies are risk factors for children's IPA.
Current diagnostic criteria differentiate between "proven," "probable," and "possible" disease.
Consecutive galactomannan assays hold good sensitivity and specificity, mainly when executed on broncho-alveolar lavage.
Simultaneously, β-D-glucan should not be used as the cut-off in children is unclear.
PCR assays are not currently advised to use routinely.
Voriconazole remains the first-line agent for IPA in children aged >2 years.
Liposomal amphotericin B is advised in younger patients or cases intolerant to voriconazole.
Plasma concentrations of Liposomal amphotericin B should be monitored throughout the treatment.
The optimal duration of therapy still needs to be established.
Posaconazole is the preferred prophylactic agent in children >13 years old, while oral voriconazole or itraconazole are the drugs of choice for those between 2–12 years.
Further good-quality studies are needed to improve clinical practice.

Terlizzi V, Motisi MA, Pellegrino R. et al. Management of pulmonary aspergillosis in children: a systematic review. Ital J Pediatr. 2023; 49. https://doi.org/10.1186/s13052-023-01440-9

IJCP Editorial Team

Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.